A Population-based, Multicenter Cohort Study of Combined Screening for Gastrointestinal Tumors

Digestive Disease Clinical Trial

Official title:

A Population-based, Multicenter Cohort Study of Combined Screening for Gastrointestinal Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05996458
• Other study ID #: KY20232111-F-1?
• Status: Recruiting
• Start date: August 1, 2023
• Est. completion date: June 30, 2033

Study information

• Verified date: July 2023
• Source: Xijing Hospital
• Contact: rong zheng
• Phone: 19829758242
• Email: zhengrong4956[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To establish combined gastroenteroscopy screening and follow-up management for gastrointestinal tumors, explore and evaluate the feasibility and health economic benefits of combined screening for esophagus, stomach and colorectal cancer

Description:

group one: The screening population will undergo gastroscopy, colonoscopy, fecal occult blood test (FIT), Helicobacter pylori (HP) antigen test, ring finger protein 180 (RNF180) and SEPTIN9 gene methylation test, and investigation of risk factors, including past disease history, alcohol drinking history, smoking history, tea drinking history, family history of cancer, marital and reproductive status, and dietary habits. group two: The screening population will undergo investigation of risk factors, a fecal occult blood test (FIT), and a stool test for Helicobacter pylori (HP) antigen. If a stool occult blood test or H. pylori antigen is positive after testing, RNF180 and SEPTIN9 gene methylation testing will be scheduled. If the gene methylation test is positive, a colonoscopy will be scheduled. Group one's control（Spouse or sibling of group one);group two's control（Spouse or sibling of group one): Only the risk factors will be investigated, including previous disease history, drinking history, smoking history, drinking history, family history of malignant tumor, marriage and childbearing status, eating habits, etc. Finally, 10 years follow-up will be conducted to observe the outcome

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 84000
• Est. completion date: June 30, 2033
• Est. primary completion date: November 30, 2032
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 45 Years to 70 Years

Eligibility

Inclusion Criteria:

• 1. Subjects were 45 to 70 years old when enrolled 2. Willing and able to sign informed consent

Exclusion Criteria:

• 1. History of any type of malignancy 2. Previous resection of esophagus, stomach or colorectal 3. Received gastrointestinal endoscopy such as colonoscopy and gastroscopy in recent 5 years 4. Have received fecal occult blood test and fecal DNA test in the past 1 year. 5. Contraindications to endoscopy. 6. Warning symptoms of digestive tract

tumors, including:

1. Difficulty swallowing, choking or halting feeling when eating recently

2. Recent esophageal foreign body sensation or swallowing pain

3. Recent long-term loss of appetite and appetite

4. Recent and prolonged symptoms of indigestion (including acid reflux, heartburn, abdominal grumbling, burping, nausea or premature satiety, etc.)

5. Recent symptoms of abdominal mass, abdominal pain, vomiting or hematemesis

6. It was medically diagnosed as iron deficiency anemia

7. Recent changes in hematochezia, black stool or stool character and frequency

8. Recent symptoms of perianal discomfort (including soreness, itching, lumps, prolapse or other discomfort)

9. Unexplained weight loss (more than 10% of base body weight) in the past 6 months Step 7 Get pregnant 8. There are other serious comorbiditions that reduce screening benefits (including severe lung disease, advanced kidney disease, advanced liver disease, severe heart failure, etc.)

Related Conditions & MeSH terms

• Digestive Disease
• Digestive System Diseases
• Digestive System Neoplasms
• Gastrointestinal Diseases
• Gastrointestinal Neoplasms

Intervention

Other:
• Gastroenteroscopy;Risk factor investigation; FIT-HP;RNF180 and SEPTIN9 gene methylation test
group one: The screening population will undergo gastroscopy, colonoscopy, fecal occult blood test (FIT), Helicobacter pylori (HP) antigen test, RNF180/Septin9 gene methylation test, and investigation of risk factors, including past disease history, alcohol drinking history, smoking history, tea drinking history, family history of cancer, marital and reproductive status, and dietary habits.
• Risk factor investigation;
Only the risk factors will be investigated, including previous disease history, drinking history, smoking history, drinking history, family history of malignant tumor, marriage and childbearing status, eating habits, etc.
• Gastroenteroscopy;Risk factor investigation; FIT-HP;RNF180 and SEPTIN9 gene methylation test
group two: The screening population will undergo investigation of risk factors, a fecal occult blood test (FIT), and a stool test for Helicobacter pylori (HP) antigen. If a stool occult blood test or H. pylori antigen is positive after testing, RNF180 and SEPTIN9 gene methylation testing will be scheduled. If the gene methylation test is positive, a colonoscopy will be scheduled.

Locations

Country	Name	City	State
China	Gaoyao District People's Hospital	Zhaoqing	Guangzhou

Sponsors (1)

Lead Sponsor	Collaborator
Xijing Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cancer or precancerous lesions detected	Cancer or precancerous lesions detected	10 year